Fenofibrate/simvastatin

Fenofibrate/simvastatin
Combination of
FenofibrateFibrate
SimvastatinStatin
Clinical data
Trade namesCholib
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]

It was approved for use in the European Union in August 2013.[1]

Medical uses

Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]

Adverse effects

See also: Fenofibrate § Adverse_effects, and Simvastatin § Adverse_effects

References

  1. ^ a b c d e "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Archived from the original on 12 November 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.